Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040622041> ?p ?o ?g. }
- W2040622041 endingPage "391" @default.
- W2040622041 startingPage "391" @default.
- W2040622041 abstract "Dabrafenib and its potential for the treatment of metastatic melanoma Alexander M Menzies,1 Georgina V Long,1,2 Rajmohan Murali3,41Melanoma Institute Australia, Sydney, New South Wales, Australia; 2Westmead Institute for Cancer Research and Crown Princess Mary Cancer Centre Westmead, Sydney, New South Wales, Australia; 3Department of Pathology; 4Human Oncology and Pathogensis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USAAbstract: The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving role of dabrafenib in treatment for melanoma patients. Fifty percent of cutaneous melanomas have mutations in BRAF, resulting in elevated activity of the mitogen-activated protein kinase signaling pathway. Dabrafenib inhibits the mutant BRAF (BRAFmut) protein in melanomas with BRAFV600E and BRAFV600K genotypes. BRAFV600E metastatic melanoma patients who receive dabrafenib treatment exhibit high clinical response rates and compared with dacarbazine chemotherapy, progression-free survival. Efficacy has also been demonstrated in BRAFV600K patients and in those with brain metastases. Dabrafenib has a generally mild and manageable toxicity profile. Cutaneous squamous cell carcinomas and pyrexia are the most significant adverse effects. Dabrafenib appears similar to vemurafenib with regard to efficacy but it is associated with less toxicity. It is expected that new combinations of targeted drugs, such as the combination of dabrafenib and trametinib (GSK1120212, a MEK inhibitor), will provide higher response rates and more durable clinical benefit than dabrafenib monotherapy.Keywords: BRAF mutation, BRAF inhibitor, clinical trial, GSK1120212, GSK2118436, vemurafenib" @default.
- W2040622041 created "2016-06-24" @default.
- W2040622041 creator A5022520811 @default.
- W2040622041 creator A5055849515 @default.
- W2040622041 creator A5071577704 @default.
- W2040622041 date "2012-12-01" @default.
- W2040622041 modified "2023-10-13" @default.
- W2040622041 title "Dabrafenib and its potential for the treatment of metastatic melanoma" @default.
- W2040622041 cites W1768812886 @default.
- W2040622041 cites W1773110831 @default.
- W2040622041 cites W1819015028 @default.
- W2040622041 cites W1917632054 @default.
- W2040622041 cites W1950572133 @default.
- W2040622041 cites W1967953130 @default.
- W2040622041 cites W1968221752 @default.
- W2040622041 cites W1971947883 @default.
- W2040622041 cites W1984293031 @default.
- W2040622041 cites W1986067358 @default.
- W2040622041 cites W1986426976 @default.
- W2040622041 cites W1988379285 @default.
- W2040622041 cites W1989121777 @default.
- W2040622041 cites W1996429288 @default.
- W2040622041 cites W2001710734 @default.
- W2040622041 cites W2004015477 @default.
- W2040622041 cites W2004295816 @default.
- W2040622041 cites W2007032547 @default.
- W2040622041 cites W2014565000 @default.
- W2040622041 cites W2017187984 @default.
- W2040622041 cites W2019544036 @default.
- W2040622041 cites W2019607817 @default.
- W2040622041 cites W2023046293 @default.
- W2040622041 cites W2024449289 @default.
- W2040622041 cites W2025600760 @default.
- W2040622041 cites W2032211985 @default.
- W2040622041 cites W2034048944 @default.
- W2040622041 cites W2038504586 @default.
- W2040622041 cites W2043058822 @default.
- W2040622041 cites W2043336272 @default.
- W2040622041 cites W2048618556 @default.
- W2040622041 cites W2051165598 @default.
- W2040622041 cites W2053473615 @default.
- W2040622041 cites W2053520756 @default.
- W2040622041 cites W2054292405 @default.
- W2040622041 cites W2055366803 @default.
- W2040622041 cites W2055624262 @default.
- W2040622041 cites W2056199226 @default.
- W2040622041 cites W2056918351 @default.
- W2040622041 cites W2069032357 @default.
- W2040622041 cites W2072313415 @default.
- W2040622041 cites W2073363047 @default.
- W2040622041 cites W2076071381 @default.
- W2040622041 cites W2077517114 @default.
- W2040622041 cites W2077804275 @default.
- W2040622041 cites W2091100650 @default.
- W2040622041 cites W2093801202 @default.
- W2040622041 cites W2097995306 @default.
- W2040622041 cites W2098405842 @default.
- W2040622041 cites W2100614336 @default.
- W2040622041 cites W2101653483 @default.
- W2040622041 cites W2102584939 @default.
- W2040622041 cites W2103220202 @default.
- W2040622041 cites W2103675014 @default.
- W2040622041 cites W2103845135 @default.
- W2040622041 cites W2104096707 @default.
- W2040622041 cites W2104919212 @default.
- W2040622041 cites W2105747169 @default.
- W2040622041 cites W2106494998 @default.
- W2040622041 cites W2106543129 @default.
- W2040622041 cites W2106726562 @default.
- W2040622041 cites W2106981111 @default.
- W2040622041 cites W2108480019 @default.
- W2040622041 cites W2114847324 @default.
- W2040622041 cites W2116376943 @default.
- W2040622041 cites W2118033606 @default.
- W2040622041 cites W2118863192 @default.
- W2040622041 cites W2119081353 @default.
- W2040622041 cites W2123363005 @default.
- W2040622041 cites W2128542677 @default.
- W2040622041 cites W2131001269 @default.
- W2040622041 cites W2131819768 @default.
- W2040622041 cites W2132992059 @default.
- W2040622041 cites W2133857293 @default.
- W2040622041 cites W2134471382 @default.
- W2040622041 cites W2134490812 @default.
- W2040622041 cites W2134630203 @default.
- W2040622041 cites W2135925159 @default.
- W2040622041 cites W2136474966 @default.
- W2040622041 cites W2139248078 @default.
- W2040622041 cites W2140765540 @default.
- W2040622041 cites W2141674733 @default.
- W2040622041 cites W2146306052 @default.
- W2040622041 cites W2148171430 @default.
- W2040622041 cites W2149662085 @default.
- W2040622041 cites W2153105757 @default.
- W2040622041 cites W2155305032 @default.
- W2040622041 cites W2155381255 @default.
- W2040622041 cites W2155461614 @default.
- W2040622041 cites W2155777530 @default.